In addition, AZD1775 sensitizes acute myelogenous leukemia to cytarabine, medulloblastoma cell lines to cisplatin, and high-grade glioma cell lines to irradiation, independently of p53 functionality (Porter et al., 2012; Harris et al., 2014; Mueller et al., 2014). Here, TP53 is linked to medulloblastoma.